Company / Revenue per Share
Regeneron Pharmaceuticals Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$126.15
FY2025
5-year range
$57.22 / $126.15
FY2021-FY2025
Trend
+0.8%
vs FY2024
Sector context
#2 of 154
Health Care
What the data says
Among 154 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for revenue per share. Revenue per Share has increased for 5 consecutive years, from $44.82 in FY2020 to $126.15 in FY2025.
Based on SEC 10-K filings.
126.15 in FY2025 with a 5-year CAGR of +23.0%. Ranks 2nd among 154 companies in Health Care.
Improved from $116.91 to $126.15 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +19.6%
- 5-Year CAGR
- +23.0%
- 10-Year CAGR
- -
Sector benchmark
+735.9% above sector average
Key checks
Key Insights
- Regeneron Pharmaceuticals's revenue per share has grown for 5 consecutive years.
- In FY2025, revenue per share increased 0.8% year-over-year.
- Ranks #2 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $126.15 | +0.8% |
| FY2024 | $125.13 | +7.0% |
| FY2023 | $116.91 | +58.4% |
| FY2022 | $73.82 | +29.0% |
| FY2021 | $57.22 | +27.7% |
| FY2020 | $44.82 | -20.8% |
| FY2019 | $56.58 | +27.9% |
| FY2018 | $44.24 | +286.5% |
| FY2017 | $11.45 | -73.3% |
| FY2016 | $42.86 | +16.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026